HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Different forms of obesity as a function of diet composition.

AbstractOBJECTIVE:
To characterize the phenotype of obesity on a high-carbohydrate diet (HCD) as compared to a high-fat diet (HFD) or moderate-fat diet (MFD).
METHODS AND PROCEDURES:
In four experiments, adult Sprague-Dawley rats (275-300 g) were maintained for several weeks on a: (1) HFD with 50% fat; (2) balanced MFD with 25% fat; or (3) HCD with 10% fat/65% carbohydrate. Then, based on the amount of body fat accumulated in four dissected fat pads, the animals were subgrouped as lean (lowest tertile) or obese (highest tertile) and characterized with multiple measures.
RESULTS:
The obese rats of these diet groups, with 70-80% greater body fat than the lean animals, exhibited elevated levels of leptin and insulin and increased activity of lipoprotein lipase in adipose tissue (aLPL), with no change in muscle LPL. Characteristics common to the obese rats on the HFD or MFD, but not seen on the HCD, were hyperphagia, elevated circulating levels of triglycerides (TG), nonesterified fatty acids (NEFA) and glucose, and a significant increase in beta-hydroxyacyl-CoA dehydrogenase (HADH) activity in muscle, reflecting its greater capacity to metabolize fat. This was accompanied by a significant increase in expression of the peptide, galanin (GAL), in the paraventricular nucleus (PVN), as measured by in situ hybridization and real-time quantitative PCR, and also in GAL peptide immunoreactivity. These measures of GAL were consistently, positively correlated with circulating TG levels and also with HADH activity in muscle. In contrast to these fat-associated changes, rats that became obese on an HCD maintained normal caloric intake and levels of TG, NEFA, and glucose. They also showed no change in PVN GAL mRNA or peptide. Instead, they exhibited a significant reduction in HADH activity compared to the lean animals, along with increased activity of phosphofructokinase in muscle, a key enzyme in glycolysis.
CONCLUSION:
Specific characteristics of obesity, including expression of hypothalamic peptides, are dependent upon diet composition. Whereas obesity on an HFD is associated with hyperphagia and elevated lipids, fat metabolism in muscle, and fat-stimulated peptides such as GAL, obesity on an HCD with a similar increase in body fat shows none of these characteristics and instead exhibits a metabolic pattern in muscle that favors carbohydrate over fat oxidation. These results suggest the existence of multiple forms of obesity with different underlying mechanisms that are diet dependent.
AuthorsJ T Dourmashkin, G-Q Chang, E C Gayles, J O Hill, S K Fried, C Julien, S F Leibowitz
JournalInternational journal of obesity (2005) (Int J Obes (Lond)) Vol. 29 Issue 11 Pg. 1368-78 (Nov 2005) ISSN: 0307-0565 [Print] England
PMID16088331 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Blood Glucose
  • Dietary Carbohydrates
  • Dietary Fats
  • Fatty Acids, Nonesterified
  • Insulin
  • Leptin
  • RNA, Messenger
  • Triglycerides
  • Galanin
  • 3-Hydroxyacyl CoA Dehydrogenases
  • Phosphofructokinase-1
  • Lipoprotein Lipase
Topics
  • 3-Hydroxyacyl CoA Dehydrogenases (analysis)
  • Animals
  • Blood Glucose (analysis)
  • Body Composition
  • Dietary Carbohydrates (administration & dosage)
  • Dietary Fats (administration & dosage, adverse effects)
  • Energy Intake
  • Fatty Acids, Nonesterified (blood)
  • Galanin (analysis, genetics)
  • Hyperphagia (etiology)
  • Insulin (blood)
  • Leptin (blood)
  • Lipoprotein Lipase (blood)
  • Male
  • Muscle, Skeletal (enzymology)
  • Obesity (blood, etiology, physiopathology)
  • Paraventricular Hypothalamic Nucleus (chemistry)
  • Phosphofructokinase-1 (analysis)
  • Prospective Studies
  • RNA, Messenger (analysis)
  • Rats
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: